Regenersis revives

Companies: FON   
17/09/2008

The fully listed company, which handles product management to consumer and commercial technology concerns, increased turnover nine per cent to £105 million in the year to June. Chief executive officer Gary Stokes says these results reflect a thorough restructuring and re-branding process, which has Regenersis with two core service areas: repairs and environmental.

He points out the company doubled its gross operating margins and paid off its debts in 2007 to 2008, ending the financial year with £1 million cash. The company managed to renegotiate a £16 million banking facility in February and, says Stokes, now has adequate ‘headroom’ to make investments in new facilities which may not reap instant returns but should pay off in growth and profits in the longer term.

Stokes suggests Regenersis will be in a position to pay a dividend at the end of the current year on its shares, which fell from 164.5p in 2006 to 54.5p last February. Recommended by Growth Company Investor at 57.5p in March, they have now reached 80p and could rally further, overall stock market conditions permitting.

Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.

Robert Tyerman

Related Articles:
16/05/2008
16/05/2008
15/05/2008
14/05/2008
14/05/2008

AIM0pm p p
Other company articles:
06/10/2008
17/09/2008
10/05/2005

Sponsored Listings

Manage Your Finances Money, tax and benefits : your official guide.

Agency Commercial Mortgage Looking for Agency Commercial Mortgage? Search over 15,000 sites with one click. Your source for everything under the sun.

Agency Commercial Mortgage - Check Out I Found It All the top companies and links for agency commercial mortgage under one roof at I-Found-It.

Recommendations

EBTM

SELL

Dmatek

ACCEPT OFFER

Spice

BUY/HOLD

Orpak Systems

HOLD

BlueStar SecuTech

BUY

Litcomp

SPECULATIVE BUY

Theo Fennell

AVOID

Immunodiagnostic Systems

BUY/HOLD

Redstone

AVOID

Harvey Nash Group

HOLD
AIM